A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations
Authors:
- Anne T. ReutensARAnne T. Reutens
- Karin Jandeleit-DahmKarin Jandeleit-Dahm
- Merlin ThomasMTMerlin Thomas
- Agus SalimASAgus Salim
- Alysha M. De LiveraALAlysha M. De Livera
- Leon A. BachLBLeon A. Bach
- Peter G. ColmanPCPeter G. Colman
- Timothy M.E. DavisTimothy M.E. Davis
- Elif I. EkinciEEElif I. Ekinci
- Greg FulcherGFGreg Fulcher
- Peter Shane HamblinPHPeter Shane Hamblin
- Mark A. KotowiczMKMark A. Kotowicz
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 90, 105892
Abstract
No abstract availableKeywords
Funding Information
- Abbott Laboratories
- Juvenile Diabetes Research Foundation Australia
- Novartis
- Bristol-Myers Squibb
- Novo Nordisk
- Roche
- Eli Lilly and Company
- Mount Sylvia Diatomite
- AbbVie
- AstraZeneca
- Servier
- Boehringer Ingelheim
- Baker Heart and Diabetes Institute
- Australian Research Council
- Merck
- Sanofi Australia
- Bayer
This publication has 12 references indexed in Scilit:
- Albuminuria Is an Appropriate Therapeutic Target in Patients with CKDClinical Journal of the American Society of Nephrology, 2015
- Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetesAmerican Journal of Physiology-Renal Physiology, 2015
- Upstream Regulators and Downstream Effectors of NADPH Oxidases as Novel Therapeutic Targets for Diabetic Kidney DiseaseMolecules and Cells, 2015
- GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug AdministrationAmerican Journal of Kidney Diseases, 2014
- Genetic Targeting or Pharmacologic Inhibition of NADPH Oxidase Nox4 Provides Renoprotection in Long-Term Diabetic NephropathyJournal of the American Society of Nephrology, 2014
- NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated AtherosclerosisCirculation, 2013
- Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetesClinical Science, 2012
- Oxidative Stress in Diabetic NephropathyCurrent Medicinal Chemistry, 2010
- The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 DiabetesDiabetes, 2009
- Molecular mechanisms of hypertension: role of Nox family NADPH oxidasesCurrent Opinion in Nephrology and Hypertension, 2009